Protalix BioTherapeutics Sustainability Profile
Protalix BioTherapeutics, a pioneering biopharmaceutical company headquartered in Israel, focuses on developing and commercialising innovative therapies for rare diseases. Founded in 2003, Protalix has made significant strides in the biotechnology sector, particularly in the production of therapeutic proteins using its proprietary plant cell-based expression system. The company’s flagship product, Elelyso, is a unique enzyme replacement therapy for Gaucher disease, showcasing Protalix's commitment to addressing unmet medical needs. With a strong emphasis on research and development, Protalix BioTherapeutics has positioned itself as a leader in the biopharmaceutical industry, achieving notable milestones in regulatory approvals and partnerships. Its operational reach extends beyond Israel, impacting patients globally with its cutting-edge therapies.
DitchCarbon Score
How does Protalix BioTherapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Protalix BioTherapeutics's score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Protalix BioTherapeutics's reported carbon emissions
Protalix BioTherapeutics, headquartered in Israel (IL), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Protalix BioTherapeutics appears to lack formal commitments to carbon reduction initiatives or industry-standard climate frameworks such as the Science Based Targets initiative (SBTi). Without available emissions data or reduction strategies, it is unclear how the company is addressing its environmental impact or contributing to broader climate goals within the biopharmaceutical sector. In the context of the industry, many companies are increasingly adopting sustainability measures and setting ambitious targets to reduce their carbon footprints. However, Protalix BioTherapeutics has yet to publicly align with such initiatives or disclose relevant emissions data.
How Carbon Intensive is Protalix BioTherapeutics's Industry?
How Carbon Intensive is Protalix BioTherapeutics's Location?
Protalix BioTherapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Protalix BioTherapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
